{"id":"W2129929638","doi":"10.1128/aac.00149-07","title":"In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1","year":2007,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; Micropharma (Canada); PerkinElmer Biosignal","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Nelfinavir; Amprenavir; Saquinavir; Indinavir; Lopinavir; Protease; Virology; Biology; Ritonavir; Protease inhibitor (pharmacology); Atazanavir; Virus; Drug resistance; Viral load; Microbiology; HIV-1 protease; Enzyme; Biochemistry; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000212003,0.0003964242,0.000294448,0.000162857,0.0000968087,0.0002878099,0.0001977518,0.0003484496,0.0005881649],"category_scores_gemma":[0.0003725514,0.0001423623,0.0002465128,0.000185117,0.0001571378,0.0001639164,0.0001511184,0.0004078151,0.0002813111],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002029949,"about_ca_system_score_gemma":0.0001258035,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005292562,"about_ca_topic_score_gemma":0.000559061,"domain_scores_codex":[0.9998104,0.00005839677,0.00001814494,0.00003402734,0.00005192391,0.00002717513],"domain_scores_gemma":[0.9998592,0.00006219785,0.00002194791,0.00001588323,0.00001978206,0.00002093515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002399835,0.0002044398,0.0007736883,0.00004967001,0.00001896183,0.0001123834,0.0000279642,0.0008444897,0.9929454,0.00003114611,0.00004555699,0.004706512],"study_design_scores_gemma":[0.00004851935,0.003845926,0.005031276,0.000007222812,0.00004578451,0.0006712841,0.00001548905,0.001800008,0.9871149,0.00003331571,0.001378255,0.000008024348],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953251,0.002494002,0.0009390126,0.00003160327,0.00001090776,0.00002583756,0.00023099,0.00002068464,0.0009218507],"genre_scores_gemma":[0.9945937,0.001706561,0.001531549,0.00006734931,0.00001281871,0.00002581114,0.001165971,0.00001202318,0.0008842732],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0005881649,"threshold_uncertainty_score":0.001967669,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01476694695398431,"score_gpt":0.2981155288827982,"score_spread":0.2833485819288138,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}